News | Jacobio Pharma

51 press releases in total

2023

Mar 15, 2023

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

[More]
Jan 8, 2023

Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S.

[More]

2022

Dec 16, 2022

Jacobio’s KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE

[More]
Dec 2, 2022

Jacobio’s Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022

[More]
Oct 29, 2022

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 in China

[More]
Oct 13, 2022

Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

[More]
Sep 16, 2022

Jacobio Completes First Patient Dosage of JAB-21822’s Phase II Pivotal Study in China

[More]
Sep 6, 2022

Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-21822’s Phase II Pivotal Study in China

[More]
Sep 2, 2022

Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China

[More]
Sep 1, 2022

Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China

[More]
Aug 23, 2022

Jacobio Announces 2022 Interim Results

[More]
May 27, 2022

Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting

[More]
Mar 28, 2022

Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from China CDE

[More]
Mar 23, 2022

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

[More]
Feb 24, 2022

Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

[More]
Jan 17, 2022

Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA

[More]

2021

Dec 6, 2021

Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

[More]
Oct 15, 2021

Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from FDA

[More]
Sep 1, 2021

Jacobio Pharmaceuticals Announces 2021 Interim Results

[More]
Aug 31, 2021

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

[More]

Pages